The data showed that circulating irisin levels correlated positively with muscle strength and were predictive of muscle quality and the bone formation marker P1PN, suggesting that irisin may represent a novel biomarker to help monitor the progression of muscle atrophy and bone fragility in patients with CMT14. This evidence concerns the gene FNDC5 and muscle atrophy.